Last reviewed · How we verify
Glucagon IM
Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.
Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Severe hypoglycemia in patients with diabetes.
At a glance
| Generic name | Glucagon IM |
|---|---|
| Also known as | GlucaGen® HypoKit |
| Sponsor | Eli Lilly and Company |
| Drug class | Glucagon receptor agonist |
| Target | Glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Glucagon is a peptide hormone that activates glucagon receptors (a G-protein coupled receptor) on hepatocytes, triggering intracellular signaling cascades that promote the breakdown of stored glycogen and synthesis of new glucose. This mechanism makes it effective for acute treatment of severe hypoglycemia by quickly mobilizing endogenous glucose production. The IM formulation allows for rapid absorption and onset of action in emergency settings.
Approved indications
- Severe hypoglycemia in patients with diabetes
Common side effects
- Nausea
- Vomiting
- Headache
- Hyperglycemia
Key clinical trials
- A Study Comparing User Experience of Different Delivery Devices for Glucagon (PHASE1)
- A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus (PHASE3)
- Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults (PHASE3)
- A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus (PHASE1)
- Evaluate the Immunogenicity of a Novel Glucagon Formulation (PHASE3)
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (PHASE2, PHASE3)
- Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers (PHASE1)
- Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucagon IM CI brief — competitive landscape report
- Glucagon IM updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI